Agenus Reports Significant Three-Year Survival Data for BOT+BAL in mCRC
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Source: Newsfilter
- Survival Rate Breakthrough: The fully enrolled 123-patient Phase 1b study demonstrated a median overall survival of 21.2 months and a three-year overall survival rate of 33% for the BOT+BAL combination, significantly surpassing the 10-14 months typical of conventional treatments, indicating potential advantages in refractory colorectal cancer patients.
- Good Tolerability: Extended safety follow-up revealed no new safety signals, with 98% resolution of immune-mediated diarrhea/colitis and no treatment-related deaths, suggesting that BOT+BAL has a favorable safety profile compared to traditional immunotherapies.
- Significant Treatment Effects: Among patients who had received at least three prior therapies, 21% achieved confirmed objective responses, and 17% were alive and off all systemic anticancer therapy at last follow-up, highlighting the durable efficacy of the combination.
- Clinically Meaningful Implications: These findings not only provide robust support for the use of BOT+BAL in refractory colorectal cancer but also lay the groundwork for the upcoming randomized Phase 3 BATTMAN trial, potentially reshaping treatment expectations in this field.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AGEN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AGEN
Wall Street analysts forecast AGEN stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.410
Low
23.00
Averages
23.00
High
23.00
Current: 3.410
Low
23.00
Averages
23.00
High
23.00
No data
About AGEN
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer with a comprehensive pipeline of immunological agents. The company is focused on expanding patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Its I-O portfolio is driven by several platforms and programs, which include multiple antibody discovery platforms, antibody candidate programs, its saponin-based vaccine adjuvant platform, and a pipeline of novel allogeneic invariant natural killer T cell (iNKT) therapies for treating cancer and other immune-mediated diseases, controlled by MiNK. Its antibody candidate programs include botensilimab (BOT) and balstilimab (BAL) (a PD-1 blocking antibody). The Company has secured committed manufacturing capacity to support BOT+BAL supply needs for its clinical trials, global access programs and future commercialization.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Agenus Reports Significant Three-Year Survival Data for BOT+BAL in mCRC
- Survival Rate Breakthrough: The fully enrolled 123-patient Phase 1b study demonstrated a median overall survival of 21.2 months and a three-year overall survival rate of 33% for the BOT+BAL combination, significantly surpassing the 10-14 months typical of conventional treatments, indicating potential advantages in refractory colorectal cancer patients.
- Good Tolerability: Extended safety follow-up revealed no new safety signals, with 98% resolution of immune-mediated diarrhea/colitis and no treatment-related deaths, suggesting that BOT+BAL has a favorable safety profile compared to traditional immunotherapies.
- Significant Treatment Effects: Among patients who had received at least three prior therapies, 21% achieved confirmed objective responses, and 17% were alive and off all systemic anticancer therapy at last follow-up, highlighting the durable efficacy of the combination.
- Clinically Meaningful Implications: These findings not only provide robust support for the use of BOT+BAL in refractory colorectal cancer but also lay the groundwork for the upcoming randomized Phase 3 BATTMAN trial, potentially reshaping treatment expectations in this field.
See More
Agenus to Hold Annual Shareholders Meeting in 2026
- Meeting Schedule: Agenus will hold its Annual Shareholders Meeting on June 16, 2026, at 10:00 a.m. ET in a virtual format, with registration starting at 9:45 a.m., ensuring timely participation for shareholders.
- Participation Details: Shareholders must visit www.virtualshareholdermeeting.com/AGEN2026 and enter the 16-digit control number from their proxy materials to participate, while guests can access the meeting in listen-only mode without a control number, enhancing accessibility.
- Voting Information: Shareholders of Agenus as of the April 22, 2026 record date can vote, with assistance from proxy solicitor Alliance Advisors, ensuring shareholders can effectively engage in the decision-making process.
- Company Overview: Founded in 1994, Agenus is a leading immuno-oncology company focused on expanding the patient population benefiting from cancer immunotherapy through various immunological agents, showcasing its robust R&D capabilities in antibody therapeutics and cell therapies.
See More
Noetik's TARIO-2 Platform Reveals Tumor Microenvironment Patterns
- Significant Clinical Response: Among 113 patients treated with BOT+BAL, the AI-identified subgroup exhibited a 64% response rate compared to just 9% in the remaining cohort, highlighting TARIO-2's potential in identifying patients likely to benefit from treatment.
- Improved Survival Rates: In the MSS metastatic colorectal cancer cohort without active liver metastases, the AI-identified subgroup had a median overall survival not reached, with a hazard ratio of 0.18, indicating TARIO-2's significant predictive power for survival outcomes.
- Innovative Technology Application: The TARIO-2 model analyzes standard H&E pathology images to extract biologically relevant tumor microenvironment features, offering a patient stratification strategy that does not rely on complex tissue profiling, which could transform clinical practices.
- Future Validation Plans: Agenus is set to present these findings at the 2026 ASCO Annual Meeting, aiming to validate TARIO-2 as an image-based biomarker strategy for BOT+BAL, thereby advancing the clinical development of immunotherapy.
See More
Agenus Reports New Data on HCC Treatment
- Clinical Trial Results: Agenus' Phase 1b trial data reveals that in 19 patients with treatment-refractory hepatocellular carcinoma (HCC), the combination of BOT and BAL achieved an objective response rate of 17%, including one complete response and two partial responses, indicating potential efficacy in this challenging patient population.
- Survival Analysis: Among 18 efficacy-evaluable patients, the median overall survival was reported at 12.3 months, despite 47% of the cohort having ALBI grade 2 liver function, which typically indicates poorer prognosis, thus highlighting the potential of BOT and BAL in improving survival outcomes.
- Safety Assessment: The safety profile of BOT and BAL in HCC patients was consistent with prior studies, with 68% of patients experiencing immune-mediated adverse events and no treatment-related deaths, suggesting that the combination is manageable and suitable for further investigation.
- Future Research Directions: Investigators noted that the BOT and BAL combination demonstrated promising efficacy and manageable safety in post-immunotherapy HCC patients, supporting continued exploration in this area to assess its applicability in a broader patient population.
See More
Agenus Scheduled to Announce Q1 Earnings on May 11
- Earnings Announcement Timing: Agenus (AGEN) is set to release its Q1 2023 earnings report on May 11 before the market opens, drawing significant attention from investors regarding its performance and future outlook.
- Earnings Expectations: The consensus EPS estimate stands at $2.10, with revenue expectations at $129.5 million, metrics that could directly influence investor confidence and market sentiment.
- Historical Performance Review: Over the past year, Agenus has only surpassed EPS and revenue estimates 25% of the time, indicating considerable volatility in its performance, which may affect market expectations for future results.
- Market Reaction Potential: Given Agenus's inconsistent performance in exceeding expectations, investors should closely monitor the upcoming earnings report to assess its potential impact on stock price and the necessity for strategic adjustments.
See More
Agenus Announces Q1 2026 Financial Results Release Schedule
- Financial Results Announcement: Agenus plans to release its Q1 2026 financial results before the market opens on May 11, 2026, which is expected to provide investors with the latest insights into the company's financial health, potentially impacting stock price movements.
- Annual Shareholder Meeting: The company will host a webcast in June in conjunction with its Annual Meeting of Shareholders, focusing on key strategic priorities and upcoming data milestones, aimed at enhancing investor confidence and attracting more attention.
- Clinical Trial Progress: Approximately 1,200 patients have been treated with botensilimab and balstilimab in phase 1 and phase 2 clinical trials, demonstrating clinical responses across nine metastatic late-line cancers, which may lay the groundwork for the company's future market performance.
- Development Capabilities: Agenus boasts a comprehensive pipeline of immuno-oncology agents and robust development capabilities, leveraging its clinical and commercial cGMP manufacturing facilities, which may position the company favorably in future market competition.
See More
Agenus Reports Significant Three-Year Survival Data for BOT+BAL in mCRC
- Survival Rate Breakthrough: The fully enrolled 123-patient Phase 1b study demonstrated a median overall survival of 21.2 months and a three-year overall survival rate of 33% for the BOT+BAL combination, significantly surpassing the 10-14 months typical of conventional treatments, indicating potential advantages in refractory colorectal cancer patients.
- Good Tolerability: Extended safety follow-up revealed no new safety signals, with 98% resolution of immune-mediated diarrhea/colitis and no treatment-related deaths, suggesting that BOT+BAL has a favorable safety profile compared to traditional immunotherapies.
- Significant Treatment Effects: Among patients who had received at least three prior therapies, 21% achieved confirmed objective responses, and 17% were alive and off all systemic anticancer therapy at last follow-up, highlighting the durable efficacy of the combination.
- Clinically Meaningful Implications: These findings not only provide robust support for the use of BOT+BAL in refractory colorectal cancer but also lay the groundwork for the upcoming randomized Phase 3 BATTMAN trial, potentially reshaping treatment expectations in this field.
See More
Agenus to Hold Annual Shareholders Meeting in 2026
- Meeting Schedule: Agenus will hold its Annual Shareholders Meeting on June 16, 2026, at 10:00 a.m. ET in a virtual format, with registration starting at 9:45 a.m., ensuring timely participation for shareholders.
- Participation Details: Shareholders must visit www.virtualshareholdermeeting.com/AGEN2026 and enter the 16-digit control number from their proxy materials to participate, while guests can access the meeting in listen-only mode without a control number, enhancing accessibility.
- Voting Information: Shareholders of Agenus as of the April 22, 2026 record date can vote, with assistance from proxy solicitor Alliance Advisors, ensuring shareholders can effectively engage in the decision-making process.
- Company Overview: Founded in 1994, Agenus is a leading immuno-oncology company focused on expanding the patient population benefiting from cancer immunotherapy through various immunological agents, showcasing its robust R&D capabilities in antibody therapeutics and cell therapies.
See More
Noetik's TARIO-2 Platform Reveals Tumor Microenvironment Patterns
- Significant Clinical Response: Among 113 patients treated with BOT+BAL, the AI-identified subgroup exhibited a 64% response rate compared to just 9% in the remaining cohort, highlighting TARIO-2's potential in identifying patients likely to benefit from treatment.
- Improved Survival Rates: In the MSS metastatic colorectal cancer cohort without active liver metastases, the AI-identified subgroup had a median overall survival not reached, with a hazard ratio of 0.18, indicating TARIO-2's significant predictive power for survival outcomes.
- Innovative Technology Application: The TARIO-2 model analyzes standard H&E pathology images to extract biologically relevant tumor microenvironment features, offering a patient stratification strategy that does not rely on complex tissue profiling, which could transform clinical practices.
- Future Validation Plans: Agenus is set to present these findings at the 2026 ASCO Annual Meeting, aiming to validate TARIO-2 as an image-based biomarker strategy for BOT+BAL, thereby advancing the clinical development of immunotherapy.
See More
Agenus Reports New Data on HCC Treatment
- Clinical Trial Results: Agenus' Phase 1b trial data reveals that in 19 patients with treatment-refractory hepatocellular carcinoma (HCC), the combination of BOT and BAL achieved an objective response rate of 17%, including one complete response and two partial responses, indicating potential efficacy in this challenging patient population.
- Survival Analysis: Among 18 efficacy-evaluable patients, the median overall survival was reported at 12.3 months, despite 47% of the cohort having ALBI grade 2 liver function, which typically indicates poorer prognosis, thus highlighting the potential of BOT and BAL in improving survival outcomes.
- Safety Assessment: The safety profile of BOT and BAL in HCC patients was consistent with prior studies, with 68% of patients experiencing immune-mediated adverse events and no treatment-related deaths, suggesting that the combination is manageable and suitable for further investigation.
- Future Research Directions: Investigators noted that the BOT and BAL combination demonstrated promising efficacy and manageable safety in post-immunotherapy HCC patients, supporting continued exploration in this area to assess its applicability in a broader patient population.
See More
Agenus Scheduled to Announce Q1 Earnings on May 11
- Earnings Announcement Timing: Agenus (AGEN) is set to release its Q1 2023 earnings report on May 11 before the market opens, drawing significant attention from investors regarding its performance and future outlook.
- Earnings Expectations: The consensus EPS estimate stands at $2.10, with revenue expectations at $129.5 million, metrics that could directly influence investor confidence and market sentiment.
- Historical Performance Review: Over the past year, Agenus has only surpassed EPS and revenue estimates 25% of the time, indicating considerable volatility in its performance, which may affect market expectations for future results.
- Market Reaction Potential: Given Agenus's inconsistent performance in exceeding expectations, investors should closely monitor the upcoming earnings report to assess its potential impact on stock price and the necessity for strategic adjustments.
See More
Agenus Announces Q1 2026 Financial Results Release Schedule
- Financial Results Announcement: Agenus plans to release its Q1 2026 financial results before the market opens on May 11, 2026, which is expected to provide investors with the latest insights into the company's financial health, potentially impacting stock price movements.
- Annual Shareholder Meeting: The company will host a webcast in June in conjunction with its Annual Meeting of Shareholders, focusing on key strategic priorities and upcoming data milestones, aimed at enhancing investor confidence and attracting more attention.
- Clinical Trial Progress: Approximately 1,200 patients have been treated with botensilimab and balstilimab in phase 1 and phase 2 clinical trials, demonstrating clinical responses across nine metastatic late-line cancers, which may lay the groundwork for the company's future market performance.
- Development Capabilities: Agenus boasts a comprehensive pipeline of immuno-oncology agents and robust development capabilities, leveraging its clinical and commercial cGMP manufacturing facilities, which may position the company favorably in future market competition.
See More
